...

CCO Treatment Updates

Managing Ovarian Cancer Recurrence: Coupling Novel Therapeutics With Optimal Treatment Decisions

Current Standards in Recurrent Ovarian Cancer

Module 1 of 3

Faculty:

J. Tate Thigpen, MD
  • J. Tate Thigpen, MD

CREDIT INFORMATION

Release Date: 08/15/08

Expiration Date: 08/14/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.9 Nursing contact hours

Status: Please log in to view status
Begin the Module

J. Tate Thigpen, MD, provides an update on current approaches to the treatment of patients with ovarian cancer who have relapsed on or are resistant to current standard therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss options for the treatment of patients with newly diagnosed ovarian cancer
  • Describe the importance of the extent of disease at the time of initial diagnosis in determining therapy for ovarian cancer
  • Articulate the differences in treatment options between chemosensitive and chemoresistant patients with recurrent ovarian cancer
  • Cite recent data on targeted agents in the treatment of patients with recurrent or progressive ovarian cancer

Abstract

Clinical Potential of Novel Cytotoxic and Biologic Agents in Ovarian Cancer

Module 2 of 3

Faculty:

Robert A. Burger, MDLeslie Randall-Whitis, MD
  • Robert A. Burger, MD
  • Leslie Randall-Whitis, MD

CREDIT INFORMATION

Release Date: 09/19/08

Expiration Date: 09/18/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Status: Please log in to view status
Begin the Module

Robert A. Burger, MD, and Leslie Randall-Whitis, MD, review the current standard of care and emerging novel agents used in the treatment of ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Cite ongoing clinical trials of novel cytotoxic and biologic agents used in the treatment of ovarian cancer
  • Describe recent results from clinical trials of cytotoxic and biologic agents used to treat ovarian cancer
  • Discuss novel agents used to treat patients with ovarian cancer

Abstract

Current Issues and Controversies in the Treatment of Recurrent Ovarian Cancer

Module 3 of 3

Faculty:

Deborah K. Armstrong, MD
  • Deborah K. Armstrong, MD

CREDIT INFORMATION

Release Date: 09/23/08

Expiration Date: 09/22/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Status: Please log in to view status
Begin the Module

Deborah K. Armstrong, MD, reviews clinical controversies and the use of current and novel agents in the setting of recurrent ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Specify the range of current treatment options for patients with recurrent ovarian cancer
  • Describe results from recent clinical trials evaluating single-agent and combination regimens for the treatment of recurrent or platinum-resistant ovarian cancer
  • Discuss the rationale for use of novel agents with or without standard chemotherapy in the treatment of patients with recurrent ovarian cancer
  • Cite targeted agents under evaluation for the treatment of ovarian cancer

Abstract

CCO Slideset

Managing Ovarian Cancer Recurrence: Coupling Novel Therapeutics With Optimal Treatment Decisions

Download the Slideset


Download slides on the most recent data in recurrent ovarian cancer.


Format: Microsoft PowerPoint (.ppt) | File size: 943 KB | Date posted: 9/17/2008


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.